Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2025-11-13 Capital/Financing Update
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges regarding the withdrawal and status of credit ratings for certain financial instruments of the company. It references SEBI Listing Regulations and provides specific details about credit rating actions. The document is short (1814 characters) and does not contain financial statements or detailed financial analysis. It is an update on credit rating status, which relates to financing activities but is not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP).
2025-11-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice (2022 characters) informing about the company's participation in an upcoming investor conference. It references compliance with SEBI regulations and provides details about the event schedule. There is no financial data, no detailed presentation, no report attached or referenced as being published, and no discussion of financial results or corporate governance changes. The document is an announcement of participation in an investor event, not the event presentation itself. According to the classification rules, such announcements about investor conferences fall under Regulatory Filings (RNS) as they are general regulatory announcements and do not fit other specific categories.
2025-11-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an investor conference call discussing the quarterly and half-year financial results for Q2 and H1 FY 2026. It includes management commentary on financial performance, business insights, revenue growth, EBITDA margins, R&D expenses, and Q&A with analysts. The presence of detailed financial data, management discussion, and Q&A session clearly identifies this as a Call Transcript (CT) of an earnings conference call. The document is about 15,000 characters long and contains the full transcript, not just an announcement or summary. Therefore, the appropriate classification is Call Transcript (CT).
2025-11-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated November 7, 2025, informing stock exchanges about the company's participation in an upcoming investor conference. It references compliance with SEBI regulations and explicitly states that no unpublished price sensitive information will be shared. The content is an announcement of participation in an investor event rather than a detailed report or presentation. The document length is only 1581 characters, indicating it is a brief notification rather than a full investor presentation or financial report. Therefore, it fits best under the category of Investor Presentation announcements or related notices. However, since it is only an intimation of participation and not the presentation itself, the closest fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2025-11-07 English
Copy of Newspaper Publication
Regulatory Filings
2025-11-07 English
Outcome of Board Meeting
Regulatory Filings
2025-11-06 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.